Quick Links
 Topics
  Oncology
Increase Font Size  Decrease Font Size  View as PDF   Print  
 
Citation: 

Lindsey AM, Larson PJ, Dodd MJ, Brecht ML, Packer A. Comorbidity, nutritional intake, social support, weight, and functional status over time in older cancer patients receiving radiotherapy. Cancer Nurs. 1994 Apr;17(2):113-24.


PubMed ID: 8019995
Study Design: 
Prospective longitudinal study
Class: 
C - Click here for explanation of classification scheme.
Quality Rating: 
NEUTRAL: See Quality Criteria Checklist below.
Research Purpose: 
To describe the effect of specific variables (co-morbidity, nutritional intake, estimated adequacy of intake, radiation dose, side-effects, and social support) on selected outcomes (weight, functional status) in elderly breast and lung cancer patients receiving radiotherapy.
Inclusion Criteria: 
  • Histologically confirmed lung or breast cancer
  • Age > = 60 years
  • Starting radiotherapy (prophylactic, curative, or palliative)
  • Can converse and read English
  • Physician approval for study participation

Exclusion Criteria: 
Not Specified
Description of Study Protocol: 

Recruitment Patients that met inclusion criteria were invited to join the study. There is no description as to how patients were initially identified.

Design Prospective observational study of elderly breast and lung cancer patients receiving radiotherapy with prophylactic, curative, or palliative intent.

The following were measured at the beginning (T1), middle (approximately week 3)(T2) and conclusion (approximately week 6) (T3) of radiotherapy and 3 moths post-radiation (T4):

  • Weight as measured on scale.
  • Functional status as measured by Karnofsky Performance S tatus (KPS), Physical and Instruments Activities of Daily Living (PADL & IADL) subscales of the Functional Assessment Inventory, and the Overall Health Rating (OHR) subscale of the Functional Assessment Inventory.
  • Nutritional intake as measured by 3 day food diary. Nutrient Analysis was performed by an RD using a computer program.
  • Estimated adequacy of intake as calculated from the average intake from the 3 day food diary and the estimated energy expenditure.

Co-morbidity was measured by self report at the beginning of the study.

Radiation dose was obtained from medical recods at conclusion of radiotherapy (T3)

Side-effects as measured by Dodd's Self care Behavior Log (S-C BL) daily througout radiotherapy and for a 2-week period at T4.

Estimated energy expenditure was determined by the Harris Benedict Equation and multiplied by an activity factor of 1.5.

Social support was measued at T1 using the Norbeck Social Support Questionnaire (NSSQ).

BMI was calculated at each timepoint from measured height and weight.

Blinding used (if applicable) Not applicable

Intervention (if applicable) Not applicable

Statistical Analysis Analysis was performed using the following tests

  • t-tests (interval level variables)
  • chi square (categorical variables)
  • Pearson's correlation coefficient
  • Repeated measures analysis of variance

Data Collection Summary: 

Timing of Measurements: The following were measured at the beginning (T1), middle (approximately week 3) (T2) and conclusion (approximately week 6) (T3) of radiotherapy and 3 moths post-radiation (T4):

  • Weight as measured on scale.
  • Functional status as measured by Karnofsky Performance S tatus (KPS), Physical and Instruments Activities of Daily Living (PADL & IADL) subscales of the Functional Assessment Inventory, and the Overall Health Rating (OHR) subscale of the Functional Assessment Inventory.
  • Nutritional intake as measured by 3 day food diary. Nutrient Analysis was performed by an RD using a computer program.
  • Estimated adequacy of intake as calculated from the average intake from the 3 day food diary and the estimated energy expenditure.

Co-morbidity was measured by self report at the beginning of the study.

Radiation dose was obtained from medical recods at conclusion of radiotherapy (T3)

Side-effects as measured by Dodd's Self care Behavior Log (S-C BL) daily througout radiotherapy and for a 2-week period at T4.

Social support was measued at T1 using the Norbeck Social Support Questionnaire (NSSQ).

Dependent Variables

  • Variable 1: Weight as measured on scale at the beginning, middle and conclusion of radiotherapy and 3 moths post-radiation.
  • Variable 2: Functional status as measured by Karnofsky Performance S tatus (KPS), Physical and Instruments Activities of Daily Living (PADL & IADL) subscales of the Functional Assessment Inventory, and the Overall Health Rating (OHR) subscale of the Functional Assessment Inventory at the beginning, middle and conclusion of radiotherapy and 3 moths post-radiation.

Independent Variables

The following variables were examined as independent: co-morbidity, nutritional intake, estimated adequacy of intake, radiation dose, side-effects, and social support

Description of Actual Data Sample: 

Initial N: 45 (16 males, 29 females)

Attrition (final N): Not described

Age: Mean 69.8 (range 61-86 years)

Ethnicity: White 91.1% (n=41)

Other relevant demographics:

  • Diagnosis
    • Lung Cancer (n=26, 57.5%)

      • Stage I n=2
      • Stage III n=18
    • Breast Cancer (n=19, 42.3%)
      • Stage III n=1
  • Radiation
    • Mean dose radiation received to primary site: 4661 ± 1064 cGy
    • Mean dose radiation received to secondary site: 4293 ± 1867 cGy
  • Side effects: mean number reported
    • T1: 3.3 (n=27)
    • T2: 2.5 (n=13)
    • T3: 1.8 (n=8)
    • Most common: fatigue, skin changes
  • Comorbidity:
    • 81.4% reported at least one
    • Arthritis: 53.3% (n=24)
    • HTN: 48.9% (n=22)
    • CVD: 42.2% (n=19)
    • No significant differences between groups with and without comorbidities at any timepoint
  • Social Support
    • T1: mean 7.5 individuals important to patient
    • Functional Support Score: 149 ± 7.9
    • Network Mean Score: 70.2 ± 37.8

Anthropometrics Not described

Location: San Francisco, CA; specific location not described

Summary of Results: 

T1

T2

T3

T4

CALORIC INTAKE OVER TIME

Caloric Intake (Kcal)

1,454 ± 487

1,411 ± 386

1,417 ± 419

1,280 ± 488

Caloric Intake (% BEE)

106.8 ± 33.4

107.7 ± 27.7

103 ± 28.7

102 ± 22.7

Caloric Intake (% BEEx1.5)

71.1 ± 22.3

71.5 ± 18.7

68.6 ± 19.2

67.9 ± 15.1

Carbohydrate (% Kcal)

46.9 ± 10.5

44.9 ± 7.8

44.6 ± 9.5

41.5 ± 8.7

Protein (% Kcal)

15.4 ± 5.3

16.7 ± 3.3

18.1 ± 4.1

18.8 ± 3.3

Fat (% Kcal)

34.9 ± 8.4

34.0 ± 6.1

34.7 ± 7.7

37.1 ± 7.2

FUNCTIONAL STATUS OVER TIME

KPS (%)

78.2 ± 17.6

78.6 ± 18.0

80.4 ± 18.3

85.7 ± 14.1

PADL

25.5 ± 1.2

25.6 ± 0.9

25.5 ± 1.2

25.8 ± 0.4

IADL

28.2 ± 1.5

28.5 ± 1.2

28.7 ± 0.7

28.8 ± 0.4

OHR

6.2 ± 2.4

6.2 ± 2.2

6.5 ± 2.9

6.7 ± 3.8

T1

T2

T3

T4

Relationship Between Protein Calories and Weight/BMI

Weight T1

0.39a

BMI T1

0.53b

Weight T2

0.37a

0.52b

Weight T3

0.46a

0.47a

0.52b

BMI T3

0.47a

0.46a

Relationship Between Carbohydrate Calories and Functional Status

IADL

T1

-0.35a

T2

-0.47a

-0.38a

T3

-0.65b

-0.61b

T4

-0.59a

-0.83b

-0.67a

PADL

T1

T2

T3

-0.53a

T4

-0.60a

-.066a

KPS

T1

-0.39a

-0.66b

T2

-0.37a

-0.39a

T3

-0.37a

0.40a

T4

0.61a

a p<= 0.05; b p<= 0.01

Other Results:

  • Caloric intake not significantly correlated with weight at T1 to T3; Caloric intake significantly correlated with weight at T4 (p=0.004)
  • Calories from protein significantly correlated with weight at T1 to T3 (p=0.02, p=0.004, p=0.01); Calories from protein not significantly correlated with weight at T4
  • Caloric intake at T2 significantly to KPS at T2 (p=0.02); Caloric intake inversely significant to IADL (P=0.02)
  • Carbohydrate intake inversely significant to 2 functional status measures at each time-point.
  • Protein intake significantly associated to KPS at T2 (p=0.03) and T4 (p=0.01)
  • No relationship between 3 dimensions of social support and weight
Author Conclusion: 
Elderly patients with lung and breast cancer experienced a significant weight loss at midpoint and end of radiation therapy. Percentage of calories contributed by protein significantly positively impacted weight. There were no major disruptions in functional status during treatment.
Funding Source: 
University/Hospital: University of California, State University of California
Reviewer Comments: 

Overall a well planned study that examined many important aspects of nutritional care of elderly cancer patients. The following information limited the results:

  • Data on weight and BMI at timepoints is not presented.
  • Incomplete information on demographics (stage, ethnicity)
  • No information on patient recruitment
  • No information on where the study took place

Quality Criteria Checklist: Primary Research
Relevance Questions
  1. Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies)
Yes
  2. Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about?
Yes
  3. Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice?
Yes
  4. Is the intervention or procedure feasible? (NA for some epidemiological studies)
Yes
 
Validity Questions
1. Was the research question clearly stated?
Yes
  1.1. Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified?
Yes
  1.2. Was (were) the outcome(s) [dependent variable(s)] clearly indicated?
Yes
  1.3. Were the target population and setting specified?
Yes
2. Was the selection of study subjects/patients free from bias?
Yes
  2.1. Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study?
No
  2.2. Were criteria applied equally to all study groups?
Yes
  2.3. Were health, demographics, and other characteristics of subjects described?
Yes
  2.4. Were the subjects/patients a representative sample of the relevant population?
Yes
3. Were study groups comparable?
N/A
  3.1. Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT)
N/A
  3.2. Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline?
N/A
  3.3. Were concurrent controls used? (Concurrent preferred over historical controls.)
N/A
  3.4. If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis?
N/A
  3.5. If case control or cross-sectional study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable. Criterion may not be applicable in some cross-sectional studies.)
N/A
  3.6. If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")?
N/A
4. Was method of handling withdrawals described?
No
  4.1. Were follow-up methods described and the same for all groups?
Yes
  4.2. Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.)
N/A
  4.3. Were all enrolled subjects/patients (in the original sample) accounted for?
No
  4.4. Were reasons for withdrawals similar across groups?
No
  4.5. If diagnostic test, was decision to perform reference test not dependent on results of test under study?
N/A
5. Was blinding used to prevent introduction of bias?
No
  5.1. In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate?
N/A
  5.2. Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.)
No
  5.3. In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded?
No
  5.4. In case control study, was case definition explicit and case ascertainment not influenced by exposure status?
N/A
  5.5. In diagnostic study, were test results blinded to patient history and other test results?
N/A
6. Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described?
No
  6.1. In RCT or other intervention trial, were protocols described for all regimens studied?
N/A
  6.2. In observational study, were interventions, study settings, and clinicians/provider described?
No
  6.3. Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect?
N/A
  6.4. Was the amount of exposure and, if relevant, subject/patient compliance measured?
N/A
  6.5. Were co-interventions (e.g., ancillary treatments, other therapies) described?
No
  6.6. Were extra or unplanned treatments described?
N/A
  6.7. Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups?
N/A
  6.8. In diagnostic study, were details of test administration and replication sufficient?
N/A
7. Were outcomes clearly defined and the measurements valid and reliable?
Yes
  7.1. Were primary and secondary endpoints described and relevant to the question?
Yes
  7.2. Were nutrition measures appropriate to question and outcomes of concern?
Yes
  7.3. Was the period of follow-up long enough for important outcome(s) to occur?
Yes
  7.4. Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures?
Yes
  7.5. Was the measurement of effect at an appropriate level of precision?
Yes
  7.6. Were other factors accounted for (measured) that could affect outcomes?
Yes
  7.7. Were the measurements conducted consistently across groups?
Yes
8. Was the statistical analysis appropriate for the study design and type of outcome indicators?
Yes
  8.1. Were statistical analyses adequately described and the results reported appropriately?
Yes
  8.2. Were correct statistical tests used and assumptions of test not violated?
Yes
  8.3. Were statistics reported with levels of significance and/or confidence intervals?
Yes
  8.4. Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)?
Yes
  8.5. Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)?
Yes
  8.6. Was clinical significance as well as statistical significance reported?
Yes
  8.7. If negative findings, was a power calculation reported to address type 2 error?
N/A
9. Are conclusions supported by results with biases and limitations taken into consideration?
Yes
  9.1. Is there a discussion of findings?
Yes
  9.2. Are biases and study limitations identified and discussed?
Yes
10. Is bias due to study's funding or sponsorship unlikely?
Yes
  10.1. Were sources of funding and investigators' affiliations described?
No
  10.2. Was the study free from apparent conflict of interest?
Yes
 
 
Copyright 2013 © Academy of Nutrition and Dietetics (A.N.D.), All Rights Reserved  |  Disclaimer